课题基金 / 基金详情

Expanding the druggable genome

Expanding the druggable genome
扩大可药物基因组
批准号:
7980020
负责人:
STEPHEN W. FESIK
金额:
$77.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2015-07-31

项目摘要

项目成果

STEPHEN W. FESIK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION Abstract: Many proteins involved in protein-protein interactions are considered to be undruggable due to the large, flat binding surfaces involved in complex formation. Moreover, the current rules to obtain oral bioavailability and drug-like properties are not consistent with the type of molecules often needed to drug such challenging targets. This proposal outlines a plan to develop approaches for drugging proteins that are currently considered to be "undruggable." The strategy will involve quickly eliminating proteins with little chance of being druggable from fragment-based screens and developing better computational approaches to accomplish this goal. Optimized fragment-based methods, structure-based design, and improved computational tools will be developed for lead identification and optimization. To obtain molecules with good oral bioavailability, the current rules concerning druglikeness will be challenged, and the importance of molecular size, flexibility, polar surface area, charge, and other parameters will be examined systematically. In addition, assays will be developed to identify the reasons for the lack of bioavailability to determine how to correct these deficiencies. By synthesizing and testing compounds (including control compounds) in multiple assays in a systematic fashion, the guidelines and approaches for drugging challenging targets will be established. This research could revolutionize our approach to drug discovery, lead to new drugs to better treat disease in all therapeutic areas, and thus have a dramatic impact on human health. Public Health Relevance: Of the 30,000 proteins in the human genome, only about 3,000 are thought to be druggable by small organic molecules; however, many of these undruggable proteins are highly validated and could serve as important targets in drug discovery providing suitable approaches are developed to drug these technically challenging targets. Expanding the druggable genome as outlined in this proposal could a
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Validating the protein binding domain of replication protein A as a cancer target
  • 批准号:
    8631295
  • 项目类别:
  • 资助金额:
    $32.53万
  • 财政年份:
    2014
  • 负责人:
    STEPHEN W. FESIK
  • 依托单位:
Validating the protein binding domain of replication protein A as a cancer target
  • 批准号:
    8829791
  • 项目类别:
  • 资助金额:
    $32.58万
  • 财政年份:
    2014
  • 负责人:
    STEPHEN W. FESIK
  • 依托单位:
Validating the protein binding domain of replication protein A as a cancer target
  • 批准号:
    9037504
  • 项目类别:
  • 资助金额:
    $32.58万
  • 财政年份:
    2014
  • 负责人:
    STEPHEN W. FESIK
  • 依托单位:
Expanding the druggable genome
  • 批准号:
    8515978
  • 项目类别:
  • 资助金额:
    $74.9万
  • 财政年份:
    2010
  • 负责人:
    STEPHEN W. FESIK
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: